Low-Dose Colchicine May Help Stabilize Coronary Plaques
METHODOLOGY:
Elevated attenuation of pericoronary adipose tissue and a high burden of noncalcified plaque have been linked to adverse coronary outcomes caused by plaque rupture and instability; statins mitigate these risks by promoting plaque calcification.
This cross-sectional substudy of the LoDoCo2 trial investigated if treatment with low-dose colchicine would attenuate coronary inflammation, as evidenced by less attenuation of pericoronary adipose tissue in 151 patients with chronic coronary disease (mean age, 64.4 years; 14% women).
Patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily; n = 79) or placebo (n = 72).
All patients had previously undergone coronary stenting at enrollment and were on antiplatelet and/or anticoagulant therapy; high-intensity statin therapy consisted of 40 mg and 80 mg doses of atorvastatin.
After a median treatment duration of 28 months, coronary CT angiography (CCTA) was performed to evaluate the attenuation of pericoronary adipose tissue in the proximal segments of epicardial coronary arteries and to assess plaque characteristics.
TAKEAWAY:
Median attenuation did not differ significantly between the patients receiving colchicine and those receiving placebo.
Compared with patients receiving placebo, those receiving colchicine showed a higher calcified plaque burden (adjusted difference, 2.4%), higher calcified plaque volume (adjusted difference, 59 mm 3 ), and higher volume of dense calcified plaque (adjusted difference, 61.5 mm 3 ; P < .05 for all).
), and higher volume of dense calcified plaque (adjusted difference, 61.5 mm ; < .05 for all). In patients on low-intensity statin therapy, colchicine treatment was associated with a lower burden of low-attenuation plaque, an effect not observed in those receiving high-intensity statins ( P for interaction = .037).
IN PRACTICE:
Low-dose colchicine was associated with an overall higher volume of calcified plaque, particularly dense calcified plaque, as well as a lower burden of low-attenuation plaque in participants treated
with colchicine and low-intensity statins,' the researchers wrote. 'Although the cross-sectional design of the study limits causal inference, these are features of plaque stability and may partly explain the reduction in risk of cardiovascular events associated with colchicine in patients with chronic coronary disease.'
SOURCE:
This study was led by Aernoud T L Fiolet, MD, PhD, of University Medical Centre Utrecht, Utrecht, the Netherlands. It was published online on May 19, 2025, in Heart .
LIMITATIONS:
The researchers conducted this cross-sectional analysis at the end of treatment, without any baseline or temporal studies. This study had relatively fewer women than the proportion of women with cardiovascular disease in the general population. Additional imaging modalities were not used to confirm the findings from CCTA.
DISCLOSURES:
This study received grants from the Australian National Institutes of Health/National Heart, Lung, and Blood Institute, Withering Stichting Nederland, the Netherlands Heart Foundation, and the Netherlands Organisation for Health Research and Development. One author reported receiving software royalties from Cedars-Sinai Medical Center. Another author reported giving presentations, and three authors reported serving as consultants for pharmaceutical and healthcare companies without receiving any personal fees.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Tomé on Bonmatí's fitness ahead of the Euro 2025
Montse Tomé, head coach of the Spanish women's national team, discusses Aitana Bonmatí's fitness ahead of the Euro 2025. The FC Barcelona midfielder has just recovered from a viral meningitis.
Yahoo
2 hours ago
- Yahoo
Healthy babies born in Britain after scientists used DNA from three people to avoid genetic disease
LONDON (AP) — Eight healthy babies were born in Britain with the help of an experimental technique that uses DNA from three people to help mothers avoid passing devastating rare diseases to their children, researchers reported Wednesday. Most DNA is found in the nucleus of our cells, and it's that genetic material — some inherited from mom, some from dad — that makes us who we are. But there's also some DNA outside of the cell's nucleus, in structures called mitochondria. Dangerous mutations there can cause a range of diseases in children that can lead to muscle weakness, seizures, developmental delays, major organ failure and death. Testing during the in vitro fertilization process can usually identify whether these mutations are present. But in rare cases, it's not clear. Researchers have been developing a technique that tries to avoid the problem by using the healthy mitochondria from a donor egg. They reported in 2023 that the first babies had been born using this method, where scientists take genetic material from the mother's egg or embryo, which is then transferred into a donor egg or embryo that has healthy mitochondria but the rest of its key DNA removed. The latest research 'marks an important milestone,' said Dr. Zev Williams, who directs the Columbia University Fertility Center and was not involved in the work. 'Expanding the range of reproductive options … will empower more couples to pursue safe and healthy pregnancies.' Using this method means the embryo has DNA from three people — from the mother's egg, the father's sperm and the donor's mitochondria — and it required a 2016 U.K. law change to approve it. It is also allowed in Australia but not in many other countries, including the U.S. Experts at Britain's Newcastle University and Monash University in Australia reported in the New England Journal of Medicine Wednesday that they performed the new technique in fertilized embryos from 22 patients, which resulted in eight babies that appear to be free of mitochondrial diseases. One woman is still pregnant. One of the eight babies born had slightly higher than expected levels of abnormal mitochondria, said Robin Lovell-Badge, a stem cell and developmental genetics scientist at the Francis Crick Institute who was not involved in the research. He said it was still not considered a high enough level to cause disease, but should be monitored as the baby develops. Dr. Andy Greenfield, a reproductive health expert at the University of Oxford, called the work 'a triumph of scientific innovation,' and said the method of exchanging mitochondria would only be used for a small number of women for whom other ways of avoiding passing on genetic diseases, like testing embryos at an early stage, was not effective. Lovell-Badge said the amount of DNA from the donor is insignificant, noting that any resulting child would have no traits from the woman who donated the healthy mitochondria. The genetic material from the donated egg makes up less than 1% of the baby born after this technique. 'If you had a bone marrow transplant from a donor … you will have much more DNA from another person,' he said. In the U.K., every couple seeking a baby born through donated mitochondria must be approved by the country's fertility regulator. As of this month, 35 patients have been authorized to undergo the technique. Critics have previously raised concerns, warning that it's impossible to know the impact these sorts of novel techniques might have on future generations. 'Currently, pronuclear transfer is not permitted for clinical use in the U.S., largely due to regulatory restrictions on techniques that result in heritable changes to the embryo," Williams, of Columbia, said in an email. 'Whether that will change remains uncertain and will depend on evolving scientific, ethical, and policy discussions." For about a decade, Congress has included provisions in annual funding bills banning the Food and Drug Administration from accepting applications for clinical research involving techniques, 'in which a human embryo is intentionally created or modified to include a heritable genetic modification.' But in countries where the technique is allowed, advocates say it could provide a promising alternative for some families. Liz Curtis, whose daughter Lily died of a mitochondrial disease in 2006, now works with other families affected by them. She said it was devastating to be told there was no treatment for her eight-month-old baby and that death was inevitable. She said the diagnosis 'turned our world upside down, and yet nobody could tell us very much about it, what it was or how it was going to affect Lily.' Curtis later founded the Lily Foundation in her daughter's name to raise awareness and support research into the disease, including the latest work done at Newcastle University. 'It's super exciting for families that don't have much hope in their lives,' Curtis said. ___ Ungar reported from Erie, Pennsylvania. ——- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Maria Cheng And Laura Ungar, The Associated Press
Yahoo
4 hours ago
- Yahoo
Shops legally selling addictive nicotine pouches to children
Shops are legally selling addictive nicotine pouches to children just weeks after single-use vapes were banned in an effort to cut their use among young people, Trading Standards has warned. Trading Standards officers said they had found shops displaying the pouches – often in child-friendly sweet flavours and with eye-catching packaging – in plain sight at the front of counters during visits to check they were no longer selling single-use vapes. Nicotine pouches, commonly known as 'snus', are small pouches similar in shape to teabags containing nicotine, flavourings and sweeteners. Users place them under their upper lip, allowing nicotine to be absorbed into the bloodstream through the gum. They are available in flavours similar to those of vapes including Tropical Mango, Very Berry and Cherry Ice. Trading Standards said the pouches currently 'fall between the gap' of regulation of either a tobacco or a nicotine product, meaning shops can legally sell them to a child of any age. There is increasing concern about the rising popularity of nicotine pouches among school-aged children in the UK as they can easily go undetected by teachers and parents due to their discreet placement on the gum. A YouGov survey commissioned by the charity Action on Smoking and Health (Ash) found a growing awareness of nicotine pouches among under-18s – rising from 38% in 2024 to 43% in 2025. Almost 4% of teenagers also report trying the pouches, according to the poll of 2,746 youngsters aged 11 to 17. The Tobacco and Vapes Bill that is currently making its way through Parliament makes the sale of these nicotine products illegal to anyone under the age of 18. It will also introduce powers to restrict the use of child-appealing flavours, packaging and advertising as well as dictate where they can be placed in shops. The Chartered Trading Standards Institute (CTSI) is calling for the bill to be moved up the Parliamentary timetable to ensure it can be swiftly implemented. CTSI lead officer for tobacco and vapes Kate Pike said: 'We are getting increasing reports from concerned parents and teachers that shops are marketing and selling nicotine pouches to children. 'It is incredibly frustrating that there is nothing we can currently do to prevent them. 'We have been asking for an age of sale on nicotine pouches for some time and were delighted when this measure was included in the Tobacco and Vapes Bill. 'We would urge Government to ensure the bill is prioritised in the parliamentary calendar to enable it to be finalised so we can start taking action against those who either deliberately or uncaringly risk children getting hooked on a highly addictive product.' Ash chief executive Hazel Cheeseman said: 'The government has all the tools needed to address youth appeal and use of nicotine pouches in legislation before parliament. But parliamentary time has not been found to progress this legislation since April. 'In the meantime, companies, who know their marketing practices will eventually be restricted, are continuing to heavily promote pouches in ways that appeal to children. 'While they are likely to be very much less harmful than smoking, they contain nicotine which is addictive, and the long-term health impacts are not known.' A Department of Health and Social Care spokesman said: 'Our landmark Tobacco and Vapes Bill will ban the sale of nicotine pouches to under-18s and stop vapes and nicotine products from being deliberately promoted and advertised to children. 'The Bill will place nicotine pouches under the same advertising restrictions as tobacco and provides powers to regulate their nicotine limits, flavours, packaging and how they are displayed. 'It will stop the next generation from getting hooked on nicotine and put an end to the cycle of addiction and disadvantage.'
